El-Hibri Fuad Blog

Categories

• Abdul Aziz Said (1)
• Acquisition (1)
• American Society of Hematology (1)
• anthrax (10)
• Arab (2)
• BacilleCalmette-Guerin (1)
• BioDefense (2)
• Biomedical Advanced Research and Development Authority (2)
• biotech (1)
• Biothrax (5)
• Board of directors (5)
• Business (17)
• Businessweek (1)
• Busnesswire (2)
• Chairman (5)
• Chief Executive Officer (64)
• Chief financial officer (1)
• Chief Medical Officer (1)
• Clinical Research (2)
• colleagues (1)
• Dr. Mary Elizabeth King (1)
• El-Hibri (10)
• El-Hibri Peace Education Prize (4)
• Emergent BioSolutions (17)
• Emergent BioSolutions Inc. (60)
• Entrepreneur (2)
• Ernst & Young (1)
• Federal government of the United States (3)
• Financial Performance (1)
• Food and Drug Administration (15)
• Foundation (2)
• Fuad El-Hibri (65)
• Health Care (6)
• Healthcare Conference (5)
• Hudson Institute (1)
• Humanitarian aid (1)
• Infectious disease (2)
• Investors (4)
• Lansing (1)
• Linkedin (1)
• Lymphocyte (1)
• Maryland (3)
• Music (1)
• National Health Museum (1)
• NATO (1)
• Non-Hodgkin lymphoma (1)
• North Atlantic Treaty Organization (2)
• NuThrax (1)
• NYSE (1)
• Peace Education (2)
• Profile (5)
• Research and development (9)
• Resource Center (1)
• Revenue (1)
• Rockville (2)
• Scholars Program (1)
• Shareholders (4)
• Social Network (6)
• South Africa (1)
• Stock (2)
• Symposium (1)
• TB Vaccine (2)
• Tech Council of Maryland (2)
• Trubion Pharmaceuticals (3)
• Tuberculosis (1)
• U.S Government (8)
• U.S. Food and Drug Administration (20)
• Uncategorized (1)
• Washington (1)
• Yale University (4)